{"disease":{"id":"systemic-treatment","name":"systemic treatment"},"drugs":{"marketed":[{"drug_id":"hydroxychloroquine","indication_name":"Systemic lupus erythematosus treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"HYDROXYCHLOROQUINE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":75,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and reducing inflammation in the body."},{"drug_id":"flucytosine","indication_name":"Systemic Candidiasis Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancobon","generic_name":"FLUCYTOSINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Nucleoside Analog Antifungal [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"flucytosine","indication_name":"Systemic Cryptococcosis Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancobon","generic_name":"FLUCYTOSINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Nucleoside Analog Antifungal [EPC]","quality_score":65,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03210935","title":"French National Database of Rare Dermatological Cancers","phase":"","overall_status":"UNKNOWN","enrollment_count":9000,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT04249440","title":"Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1067,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT05927636","title":"Systemic Treatment Related Toxicity Identified With a Smartphone APPlication Measuring Step Count","phase":"","overall_status":"UNKNOWN","enrollment_count":411,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT06577376","title":"A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":252,"lead_sponsor_name":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","has_results":false},{"nct_id":"NCT06127407","title":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":136,"lead_sponsor_name":"Servier Bio-Innovation LLC","has_results":false},{"nct_id":"NCT05535829","title":"Molecular Markers in Predicting Response to Treatment in FH-deficient RCC Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06961201","title":"Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":94,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04464434","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT06277206","title":"A Study Using 18F-FAPI PET to Evaluate Treatment Response in Pancreatic Adenocarcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06254248","title":"Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07104149","title":"Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":29,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT03743961","title":"Geriatric Intervention Contribution on Quality of Life of Elderly Patients With Metastatic Neoplasia","phase":"","overall_status":"TERMINATED","enrollment_count":28,"lead_sponsor_name":"Institut de Cancérologie de la Loire","has_results":false},{"nct_id":"NCT07476807","title":"Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Sligo General Hospital","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}